These data strongly suggest that NSD2 down‐regulation is a characteristic of aging‐associated osteoporosis and imply that melatonin is efficient to restore osteogenesis capacity of BMSCs in patients with SOP. This evidence concerns the gene NSD2 and osteoporosis.